​Ardelyx, Inc. (NASDAQ:ARDX) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 27, Dennis Ding from Jefferies reiterated a Buy rating on the stock and raised the price target from $8 to $15. Earlier, on January 9, Julian Harrison from BTIG reiterated a Buy rating on Ardelyx, Inc. (NASDAQ:ARDX) and raised the price target from $14 to $17. ​Analysts from BITG noted that the positive sentiment is based on the company’s Ibsrela revenue, which grew 73% year-over-year to $274 million in f ...

WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the first patient has been dosed in ACCEL (ten-03-301), a Phase 3 clinical trial designed to assess the safety and efficacy of IBSRELA® (tenapanor) for the treatment of chronic idiopathic constipation (CIC) in adults. ACCEL is a multicenter, ...

Investors might want to bet on Ardelyx (ARDX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The powe ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.ONeil Trader is a former stockbroker turned full-time independent investor. He focuses on ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.ONeil Trader is a former stockbroker turned full-time independent investor. He focuses on ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Considering buying LRCX stock? Here’s what analysts think: Photo via Shutterstock ...

Core Viewpoint - Ardelyx (ARDX) shares experienced a significant increase of 15% to $7.76, reflecting strong investor confidence in the company's financial performance ahead of its fourth-quarter results [1][2] Financial Performance - Ardelyx reported impressive preliminary product revenue figures for 2025, with Ibsrela generating approximately $274 million, a 73% increase from 2024, and Xphozah generating about $104 million [2] - The upcoming quarterly earnings are expected to be $0.02 per share, unchanged from the previous year, with revenues projected at $118.08 million, a 1.7% increase from the year-ago quarter [3] Earnings Estimates - The consensus EPS estimate for Ardelyx has been revised 80% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [4] Industry Comparison - Ardelyx is part of the Zacks Medical - Drugs industry, where another company, Indivior PLC (INDV), saw a 1.3% increase in its stock price but has returned -10.7% over the past month [4] - Indivior's consensus EPS estimate has increased by 10% over the past month to $0.65, reflecting a year-over-year change of +103.1% [5]

Core Insights - Ardelyx (ARDX) has established itself as a strong commercial entity with two FDA-approved, first-in-class medications, indicating a robust product pipeline and market potential [1] - The company operates a dual-franchise model that is expected to drive significant revenue growth while ensuring a diversified revenue base, positioning it well for the future [1] Company Overview - Ardelyx is focused on the nephrology space, which has historically shown a strong inclination towards high-growth opportunities, suggesting a favorable market environment for its products [1] - The company’s strategy combines fundamental analysis with future trend predictions, emphasizing the importance of innovation in achieving substantial returns [1]

Ardelyx ( ARDX ) has developed into a commercial execution machine with two FDA-approved, first-in-class medications. Coming into 2026, Ardelyx has a dual-franchise model, which will allow for strong revenue growth while providing a diversified revenue floor. Historically, the nephrology space hasI have a strong inclination towards high-growth companies, often treading in sectors poised for exponential expansion. My expertise lies in understanding and investing in disruptive technologies and forward-thinkin ...

Core Viewpoint - Ardelyx (ARDX) is currently outperforming the Medical sector, with a year-to-date gain of approximately 32.8% compared to the sector's average gain of 7.5% [4]. Company Performance - Ardelyx is ranked 2 (Buy) in the Zacks Rank system, indicating a strong potential for outperforming the market in the near term [3]. - The Zacks Consensus Estimate for Ardelyx's full-year earnings has increased by 1537.5% over the past three months, reflecting improved analyst sentiment and earnings outlook [4]. - Ardelyx belongs to the Medical - Drugs industry, which has 141 individual stocks and is currently ranked 72 in the Zacks Industry Rank [6]. Industry Context - The Medical group, which includes Ardelyx, is currently ranked 5 within the Zacks Sector Rank, indicating a relatively strong position among 16 different groups [2]. - The Medical - Drugs industry has seen an average gain of 4.2% this year, further highlighting Ardelyx's superior performance [6]. - Another notable stock in the Medical sector is Halozyme Therapeutics (HALO), which has returned 7.7% year-to-date and also holds a Zacks Rank of 2 (Buy) [5].